In a wide range of cancers, angiogenesis has been found to be one of the major hurdles to responsiveness in PD-1/PD-L1 blockade therapy, limiting the infiltration and function of anti-tumor immune cells and resulting in a suboptimal anti-tumor effect [24,25,26]. The gene discussed is CD274; the disease is neoplasm.